Table 2 Significant proteins (VIP > 1) in the orthogonal partial least square discriminant analysis (OPLS-DA) model of all three compartments (intracutaneous, subcutaneous and intravenous) that contributed most to the separation in protein expression before (baseline) and after glucose provocation (Fig. 4).
Protein ID | Gene name | Protein name | Compartment | VIP | Alteration after glucose provocation vs baseline |
|---|---|---|---|---|---|
P02652 | APOA2 | Apolipoprotein A-II | Intracutaneous | 1.54 | ↑ |
Q9NZP8 | C1RL | Complement C1r subcomponent-like protein | Intracutaneous | 1.47 | ↑ |
Q96PD5 | PGLYRP2 | N-acetylmuramoyl-L-alanine amidase | Intracutaneous | 1.47 | ↑ |
P43652 | AFM | Afamin | Intracutaneous | 1.46 | ↑ |
P04217 | A1BG | Alpha-1B-glycoprotein | Intracutaneous | 1.44 | ↑ |
P02750 | LRG1 | Leucine-rich alpha-2-glycoprotein | Intracutaneous | 1.41 | ↑ |
P02765 | AHSG | Alpha-2-HS-glycoprotein | Intracutaneous | 1.39 | ↑ |
P02768 | ALB | Albumin | Subcutaneous | 1.38 | ↑ |
Q96PD5 | PGLYRP2 | N-acetylmuramoyl-L-alanine amidase | Subcutaneous | 1.37 | ↑ |
P02768 | ALB | Albumin | Intracutaneous | 1.36 | ↑ |
P00738;P00739 | HP | Haptoglobin/haptoglobin-related protein | Intravenous | 1.35 | ↑ |
P01019 | AGT | Angiotensinogen | Intracutaneous | 1.34 | ↑ |
P68871 | HBB | Hemoglobin subunit beta | Intravenous | 1.34 | ↑ |
P04217 | A1BG | Alpha-1B-glycoprotein | Intravenous | 1.34 | ↑ |
P04217 | A1BG | Alpha-1B-glycoprotein | Subcutaneous | 1.33 | ↑ |
P02766 | TTR | Transthyretin | Intracutaneous | 1.33 | ↓ |
P43251 | BTD | Biotinidase | Intracutaneous | 1.32 | ↑ |
P02652 | APOA2 | Apolipoprotein A-II | Subcutaneous | 1.30 | ↑ |
P02765 | AHSG | Alpha-2-HS-glycoprotein | Intravenous | 1.30 | ↑ |
P01019 | AGT | Angiotensinogen | Subcutaneous | 1.29 | ↑ |
P01019 | AGT | Angiotensinogen | Intravenous | 1.29 | ↑ |
P43652 | AFM | Afamin | Intravenous | 1.27 | ↑ |
P00738;P00739 | HP | Haptoglobin/haptoglobin-related protein | Intracutaneous | 1.27 | ↑ |
P02763 | ORM1 | Alpha-1-acid glycoprotein 1 | Intracutaneous | 1.27 | ↓ |
P02750 | LRG1 | Leucine-rich alpha-2-glycoprotein | Subcutaneous | 1.26 | ↑ |
P00450 | CP | Ceruloplasmin | Subcutaneous | 1.25 | ↑ |
P01011 | AACT | Alpha-1-antichymotrypsin | Subcutaneous | 1.23 | ↓ |
P02765 | AHSG | Alpha-2-HS-glycoprotein | Subcutaneous | 1.22 | ↑ |
P02750 | LRG1 | Leucine-rich alpha-2-glycoprotein | Intravenous | 1.22 | ↑ |
P02760 | AMBP | Protein AMBP | Intracutaneous | 1.22 | ↑ |
P02749 | APOH | Beta-2-glycoprotein 1 | Intracutaneous | 1.21 | ↑ |
P01011 | AACT | Alpha-1-antichymotrypsin | Intracutaneous | 1.21 | ↓ |
P68871 | HBB | Hemoglobin subunit beta | Intracutaneous | 1.20 | ↑ |
P00738;P00739 | HP | Haptoglobin/haptoglobin-related protein | Subcutaneous | 1.19 | ↑ |
P01008 | SERPINC1 | Antithrombin-III | Intravenous | 1.19 | ↓ |
P02763 | ORM1 | Alpha-1-acid glycoprotein 1 | Subcutaneous | 1.17 | ↓ |
P01042 | KNG1 | Kininogen-1 | Subcutaneous | 1.15 | ↑ |
P01042 | KNG1 | Kininogen-1 | Intracutaneous | 1.15 | ↑ |
P19652 | ORM2 | Alpha-1-acid glycoprotein 2 | Intracutaneous | 1.15 | ↓ |
P00450 | CP | Ceruloplasmin | Intracutaneous | 1.14 | ↑ |
P69905 | HBA1 | Hemoglobin subunit alpha | Intravenous | 1.14 | ↑ |
P02753 | RBP4 | Retinol-binding protein 4 | Intracutaneous | 1.13 | ↑ |
P02768 | ALB | Albumin | Intravenous | 1.13 | ↑ |
P05155 | SERPING1 | Plasma protease C1 inhibitor | Intravenous | 1.08 | ↑ |
Q9NZP8 | C1RL | Complement C1r subcomponent-like protein | Subcutaneous | 1.06 | ↑ |
P01011 | AACT | Alpha-1-antichymotrypsin | Intravenous | 1.05 | ↓ |
Q96PD5 | PGLYRP2 | N-acetylmuramoyl-L-alanine amidase | Intravenous | 1.04 | ↑ |
P68871 | HBB | Hemoglobin subunit beta | Subcutaneous | 1.04 | ↑ |
O75882 | ATRN | Attractin | Intravenous | 1.03 | ↑ |
P25311 | AZGP1 | Zinc-alpha-2-glycoprotein | Intracutaneous | 1.02 | ↓ |
P01042 | KNG1 | Kininogen-1 | Intravenous | 1.02 | ↑ |
P02753 | RBP4 | Retinol-binding protein 4 | Intravenous | 1.02 | ↓ |
P43251 | BTD | Biotinidase | Subcutaneous | 1.01 | ↑ |
